A Canadian biotech company closed nearly 8% up on Thursday at C$3.35 on the back of Phase III results on ibalizumab in patients with multi-drug resistant (MDR) HIV-1.
Theratechnologies (TSX: TH) announced that it had been notified by its partner, the Taiwanese biotechnology firm TaiMed Biologics (4147: TT), of the preliminary results for the safety and efficacy secondary endpoints of the 24-week Phase III trial.
The findings show that ibalizumab maintains significant reduction of viral load in patients with MDR HIV-1 over 24 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze